Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics
Pleuroparenchymal fibroelastosis (PPFE) is an unusual pulmonary disease with unique clinical, radiological, and pathological characteristics. Designated a rare idiopathic interstitial pneumonia in 2013, its name refers to a combination of fibrosis involving the visceral pleura and fibroelastotic changes predominating in the subpleural lung parenchyma. Although a number of disease associations have been described, no single cause of PPFE has been unequivocally identified. A diagnosis of PPFE is most commonly achieved by identifying characteristic abnormalities on computed tomographic scans. The earliest changes are consistently located in the upper lobes close to the lung apices, the same locations where subsequent disease progression is also most conspicuous. When sufficiently severe, the disease leads to progressive volume loss of the upper lobes, which, in combination with decreased body mass, produces platythorax. Once regarded as a slowly progressing entity, it is now acknowledged that some patients with PPFE follow an inexorably progressive course that culminates in irreversible respiratory failure and early death. In the absence of effective medical drug treatment, lung transplant remains the only therapeutic option for this disorder. This review focuses on improving early disease recognition and evaluating its pathophysiological impact and discusses working approaches for its management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Annals of the American Thoracic Society - 16(2019), 11 vom: 15. Nov., Seite 1351-1359 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chua, Felix [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Elastosis |
|---|
| Anmerkungen: |
Date Completed 08.10.2020 Date Revised 13.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1513/AnnalsATS.201902-181CME |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300356765 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300356765 | ||
| 003 | DE-627 | ||
| 005 | 20231225102340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1513/AnnalsATS.201902-181CME |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1001.xml |
| 035 | |a (DE-627)NLM300356765 | ||
| 035 | |a (NLM)31425665 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chua, Felix |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.10.2020 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Pleuroparenchymal fibroelastosis (PPFE) is an unusual pulmonary disease with unique clinical, radiological, and pathological characteristics. Designated a rare idiopathic interstitial pneumonia in 2013, its name refers to a combination of fibrosis involving the visceral pleura and fibroelastotic changes predominating in the subpleural lung parenchyma. Although a number of disease associations have been described, no single cause of PPFE has been unequivocally identified. A diagnosis of PPFE is most commonly achieved by identifying characteristic abnormalities on computed tomographic scans. The earliest changes are consistently located in the upper lobes close to the lung apices, the same locations where subsequent disease progression is also most conspicuous. When sufficiently severe, the disease leads to progressive volume loss of the upper lobes, which, in combination with decreased body mass, produces platythorax. Once regarded as a slowly progressing entity, it is now acknowledged that some patients with PPFE follow an inexorably progressive course that culminates in irreversible respiratory failure and early death. In the absence of effective medical drug treatment, lung transplant remains the only therapeutic option for this disorder. This review focuses on improving early disease recognition and evaluating its pathophysiological impact and discusses working approaches for its management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a elastosis | |
| 650 | 4 | |a interstitial lung disease | |
| 650 | 4 | |a intraalveolar fibrosis | |
| 650 | 4 | |a pleuroparenchymal fibroelastosis | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Desai, Sujal R |e verfasserin |4 aut | |
| 700 | 1 | |a Nicholson, Andrew G |e verfasserin |4 aut | |
| 700 | 1 | |a Devaraj, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Renzoni, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Rice, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Wells, Athol U |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the American Thoracic Society |d 2013 |g 16(2019), 11 vom: 15. Nov., Seite 1351-1359 |w (DE-627)NLM225943336 |x 2325-6621 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2019 |g number:11 |g day:15 |g month:11 |g pages:1351-1359 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1513/AnnalsATS.201902-181CME |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2019 |e 11 |b 15 |c 11 |h 1351-1359 | ||